Key facts
- NexCure’s last known valuation is $50.0M (Feb 2026).
- It has raised $22.0M; the latest was Early Stage VC ($19.0M) in Feb 2026.
- Notable investors include RA Capital Management, Cencora Ventures, Oncology Ventures.
- 1 investment vehicle was formed to buy NexCure shares in the last 12 months, reporting $145K sold to 4 investors, per SEC Form D filings.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for NexCure
- ·The full record, as it builds
Funding rounds
No funding rounds for NexCure are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Secondary demand: investment vehicles
from SEC Form D filingsIn the last 12 months, 1 investment vehicle were formed to buy NexCure shares, reporting $145K sold to 4 investors. Most recent filing Feb 2026. Vehicles like these are how secondary buyers pool demand for a name; a rising count is a demand signal.
About NexCure
Operator of outpatient oncology treatment centers intended to expand access to advanced cellular and radiopharmaceutical therapies. The Company partners with health systems to build and operate specialized outpatient treatment centers focused on delivering therapies such as CAR-T and T-cell engager treatments, enabling cancer patients access advanced therapies closer to home through specialized outpatient treatment centers.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2024
- Website
- nexcure.com/
- Ownership
- Privately Held (backing)
NexCure doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NexCure shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NexCure in its N-PORT filings yet. We sweep new filings monthly.